SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in popularity as the community rallies around its status as a long-standing parody of Bitcoin, with users debating whether its satirical roots give it staying power as a legitimate asset. Supporters are actively pointing to its unique lore, growing holder count, and high-profile endorsements as catalysts, while others remain skeptical, fueling a polarized discussion about its long-term potential in the meme coin space.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as institutional investors debate whether the sector's aggressive AI-driven rally is facing a distribution phase or a continuation setup. The community is heavily focused on the disconnect between soaring AI infrastructure capex and mounting concerns over data center cancellations, power grid constraints, and valuation premiums.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently generating significant market conversation following a Canary Capital ETF filing that has renewed institutional interest and fueled community speculation about a potential major upward move. Investors are actively debating the token's long-term meme status versus its utility as a blue-chip asset, with many focusing on its price action as a key indicator of broader altcoin market health and potential rotation from Bitcoin.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is currently trending as investors weigh strong production performance and ongoing cost-synergy gains from the Marathon Oil acquisition against broader industry concerns over softening oil prices. The community is actively discussing the stock's resilience and dividend sustainability while monitoring how geopolitical tensions might influence future energy supply dynamics.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently a focal point for investors as they anticipate a transformative FDA Biologics License Application (BLA) decision for their lead drug candidate, ivonescimab, which is being positioned as a potential disruptor in the lung cancer treatment landscape. The community is intensely focused on the company's clinical pipeline, with active discussions centering on the upcoming interim progression-free survival data and the broader competitive threat the drug poses to existing blockbuster immunotherapies.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently a focal point of intense market speculation due to its critical role as a leading supplier of Indium Phosphide substrates, which are essential for high-speed optical connectivity in AI data centers. While some market participants highlight the company's strategic importance as a supply-chain bottleneck, others are intensely debating the stock's massive valuation run-up, citing concerns over insider selling, potential future share dilution, and the company's lack of consistent profitability.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors digest news of its integration into BMW's upcoming vehicle line, sparking renewed focus on QNX's role as a foundational software layer for software-defined vehicles. Community sentiment remains polarized, with many retail holders maintaining long-term conviction in QNX's growth potential despite ongoing price volatility and frustrations over recent stock performance.

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Akoustis Technologies Inc

Akoustis Technologies has completed the sale of its assets to a subsidiary of SpaceX, formally concluding its Chapter 11 bankruptcy process. The community is actively discussing the impact of this liquidation, with many shareholders expressing that their equity positions have been wiped out following the finalization of the sale.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as investors weigh mixed sentiment regarding private credit exposure and regulatory scrutiny alongside a broader rotation into financial sector quality ahead of the upcoming earnings cycle. The community remains deeply divided, with some traders monitoring institutional positioning for potential upside momentum while others express caution over potential downside risks tied to geopolitical instability and shifting lending standards.

UFO Token stands as a pivotal amplifier within the pTGC ecosystem, strategically engineered to foster unity between the Richard Heart (RH) ecosystem and The Grays Currency. Designed with precision, UFO Token operates as a catalyst, intensifying bot activity and token volume for both its own token and PTGC. Central to its architecture is a 6% buy and sell fee structure, meticulously structured to deliver rewards to holders, LP providers, and pTGC enthusiasts alike. Leveraging the same cutting-edge technology utilized to capture fees within PTGC, UFO Token extends its reach, motivating holders of RH coins to pair them with UFO. This symbiotic relationship not only expands our network but also amplifies our volume, culminating in greater rewards for all stakeholders.

UFO Gaming

UFO Gaming is experiencing a resurgence in community discussion, driven by investors tracking technical breakout patterns and anticipation surrounding its role in the play-to-earn metaverse sector. Market participants are actively debating the token's long-term utility and potential for a recovery, with many highlighting recent project developments as a key factor in its momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rati...

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027...

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1...

Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving Average - Should You Sell?

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average - Should You Sell...

Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving Average   - Here's Why

Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Pass Above 200 Day Moving Average - Here's Why...

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from...

Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Gap Up - Time to Buy?

Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Gap Up - Here's Why...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) was the recipient of a large increase in short interest in February. As of February 27th, there was short interest totaling 4,346,005...

Vanda Pharmaceuticals (NASDAQ:VNDA) Sets New 52-Week High - What's Next?

Vanda Pharmaceuticals (NASDAQ:VNDA) Sets New 12-Month High - What's Next...

Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 8.1% - Should You Buy?

Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 8.1% - Still a Buy...

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Current Price	$7.22
Prev Close	$7.33
Open	$7.35
Dividend Yield	0.00%
50-Day Moving Average	$7.61
Beta	0.74
Avg. Volume	2.09M
PE Ratio	-1.93

52-Week High	$9.94
52-Week Low	$3.81
Market Capitalization	$426.76M
EPS (Annual)	-$3.74
Price to Book	1.30
Revenue Per Employee	$405,450.28

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VNDA News

VNDAVanda Pharmaceuticals Inc